Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Non-Current Assets (2018 - 2025)

Addex Therapeutics' Non-Current Assets history spans 8 years, with the latest figure at $5.9 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 28.06% to $5.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.9 million, a 28.06% decrease, with the full-year FY2025 number at $5.6 million, down 30.65% from a year prior.
  • Non-Current Assets came in at $5.9 million for Q4 2025, down from $6.2 million in the prior quarter.
  • The five-year high for Non-Current Assets was $10.0 million in Q2 2024, with the low at $45125.0 in Q1 2024.
  • Historically, Non-Current Assets has averaged $3.0 million across 5 years, with a median of $616825.1 in 2021.
  • Biggest five-year swings in Non-Current Assets: tumbled 89.01% in 2024 and later soared 15397.26% in 2025.
  • Year by year, Non-Current Assets stood at $650709.9 in 2021, then decreased by 27.72% to $470316.3 in 2022, then decreased by 2.37% to $459148.9 in 2023, then soared by 1674.36% to $8.1 million in 2024, then decreased by 28.06% to $5.9 million in 2025.
  • Business Quant data shows Non-Current Assets for ADXN at $5.9 million in Q4 2025, $6.2 million in Q3 2025, and $7.1 million in Q2 2025.